Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.

摘要: Abstract Purpose Although treatment advances have improved outcomes in schizophrenia, definitions of remission and recovery are still evolving. Recently proposed criteria for (mild or less on multiple core-symptom ratings at least 6 months) been applied to a 1-year study long-acting risperidone injection. Methods In 50-week, open-label trial, stable patients with schizophrenia schizoaffective disorder who received injection every 2 weeks were assessed using the Positive Negative Syndrome Scale (PANSS). Remission PANSS applied; global illness severity (Clinical Global Impressions) patient-rated health status (36-Item Short-form Health Survey) measured. Results Groups identified by initial (excluding time component). considered clinically “stable,” 68.2% (394 / 578) did not meet symptom-severity component baseline. Following long-acting, injectable treatment, 20.8% (82) nonremitted achieved symptom months, significant decreases mean total cluster scores ( P Conclusions Among previously patients, many after improvements domains status. These results warrant further as these may represent meaningful clinical endpoint an important step towards functional recovery.